CollPlant Ltd. (TASE:CLPT; OTC:CQPTY), a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products, today announced positive interim clinical trial results for VergenixSTR, intended for the treatment of tendinopathy.
Contact at CollPlant:
Chief Financial Officer
Contact at Rx Communications Group, LLC
(for US Investors)
Senior Vice President